BenevolentAI Says Achieves Third Milestone In AI-enabled Drug Discovery Collaboration With AZN

AstraZeneca Plc. (AZN.L,AZN) has selected an additional novel target for idiopathic pulmonary fibrosis for its drug development portfolio, resulting in a milestone payment to BenevolentAI, the clinical-stage AI-enabled drug discovery company said in a statement.

It is the third novel target from the collaboration that has been identified using the Benevolent Platform across two disease areas, idiopathic pulmonary fibrosis and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca. It builds upon the recent extension of the collaboration with AstraZeneca to include two new disease areas, systemic lupus erythematosus and heart failure.

As part of the collaboration, BenevolentAI integrated AstraZeneca's data into its biomedical Knowledge Graph, which includes proprietary, public and licensed data from a variety of sources including scientific literature, patents, genetics, chemistry and clinical trials.

BenevolentAI and AstraZeneca scientists work side-by-side, using the platform and Knowledge Graph to interrogate the underlying mechanisms of idiopathic pulmonary fibrosis, to frame and test hypotheses and rapidly identify novel targets.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT